pharm edaily

[Kim Jinsoo, Edaily Reporter] Yuhan Corporation announced on March 7 that Boehringer Ingelheim has decided to discontinue the development of BI3006337 (YH25724), a dual-acting GLP-1/FGF21 antibody.

Yuhan Corp. (Yuhan Corp)

The drug candidate was originally licensed out to Boehringer Ingelheim under a license and collaboration agreement signed in 2019. It was being developed as a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH) and related liver diseases.

Boehringer Ingelheim will return the rights to Yuhan Corp., which is now considering continuing the drug’s development, citing the potential to meet unmet medical needs and positive safety results observed in clinical trials.

A Yuhan Corp. representative stated that the company is not facing any financial loss, as the $40 million upfront payment and $10 million milestone payment received under the licensing agreement are non-refundable.